Program
romiplostim
Also written as “Romiplostim”, “AMG 531” and “GNR-069”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.
Drug pageRomiplostim: every studyMany companies study it; this page follows only the 38 they lead. All 90 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 252 open or running | phase 4since May 21, 2009 | Jan 27, 2005 | Sep 14, 2029phase 3 · NCT07700238 |
| Kyowa Kirinits history only | 80 open or running | phase 3since Feb 22, 2007 | Mar 20, 2006 | none ahead |
| AO GENERIUMits history only | 20 open or running | phase 3since Jan 21, 2022 | Jan 21, 2022 | none ahead |
| Geropharmits history only | 21 open or running | phase 3since Jul 4, 2024 | Dec 7, 2022 | Mar 31, 2028phase 3 · NCT06497036 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Dec 23, 2025 | Dec 23, 2025 | Oct 2029phase 3 · NCT07345000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Qilu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2025First study: phase 3 study in Treatment-naïve Severe Aplastic AnemiaFirst studyNCT07345000 · 210 planned
Ahead
- Oct 2029Primary completion: phase 3 study in Treatment-naïve Severe Aplastic AnemiaNCT07345000
TargetBeta
“Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
The one study Qilu Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07345000Treatment-naïve Severe Aplastic Anemia | 3 | Not yet recruiting | Oct 2029 | 210 |
How it is read
Names in the registry
- “Romiplostim”, 22 entries
- “AMG 531”, 6 entries
- “GNR-069”, 2 entries
- “Romiplostim N01”, 1 entry
- “GP404141”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 18 studies
- Anemia, Aplastic, 6 studies
- Myelodysplastic Syndromes, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Purpura, Thrombocytopenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.